Company intelligence / Profile preview

Sidewinder Therapeutics

San Diego, California, USAsidewinderbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Sidewinder Therapeutics, founded in San Diego in 2023 with Series A funding from OrbiMed, develops precision biologic drugs—primarily next-generation ADCs and antibody therapeutics—for cancer and rare diseases. The company uses advanced computational biology to identify highly selective molecular targets. In its first year it has advanced over five programs toward clinical candidate selection but has not yet reported any clinical trial results or disclosed specific pipeline assets.

Therapeutic areas: OncologyRare Diseases
Modalities: Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs) / antibody therapeuticsLarge molecule biologics
Industry: Biotech

Drug pipeline

1 asset

SWT012

Preclinical

Partnerships

Series A funding from OrbiMed; no major pharma partnerships disclosed yet.

Beyond the preview

Go deeper on Sidewinder Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sidewinder Therapeutics.